Subtype
Lung Squamous Cell Carcinoma
CI-CAN-00003121LSCC · LUSCExplore in graph →
37 active trials14 evidence items
- NCIt
- C3493
- OncoTree
- LUSC
- DOID
- 3907
- UMLS CUI
- C0149782
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003121LSCC · LUSCExplore in graph →
Clinical trials
141 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (24)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | terminated | Phase 1 / Phase 2 | 8 | Alaunos TherapeuticsINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | terminated | Phase 2 | 205 | Seagen Inc.INDUSTRY | 6 | Mar 10, 2025 | clinicaltrials |
| NCT02831933 |
| Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma(ENSIGN) |
| terminated |
| Phase 2 |
| 11 |
| Eric Bernicker, MDOTHER |
| 1 |
| Sep 21, 2023 |
| clinicaltrials |
| NCT03827850 | FGFR Inhibitor in FGFR Dysregulated Cancer(FIND) | terminated | Phase 2 | 22 | Lung Cancer Group CologneOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT03041181 | Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor | terminated | Phase 2 | 3 | Nasser Hanna, M.D.OTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT02926638 | Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | terminated | Phase 2 / Phase 3 | 9 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 19, 2020 | clinicaltrials |
| NCT03574818 | Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001 | terminated | Phase 2 | 1 | Montefiore Medical CenterOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT02713828 | Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung(PrE0504) | terminated | Phase 1 / Phase 2 | 13 | PrECOG, LLC.OTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT01491633 | Dasatinib in Advanced Squamous Cell Lung Cancer | terminated | Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 15, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Nov 10, 2025source: clinicaltrials